Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

Cyclophosphamide 21 Cytarabine 15 blinatumomab 13 fludarabine 12 Azacitidine 10 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Methotrexate 7 Lenalidomide 7 Dexamethasone 7 Rituximab 6 Mercaptopurine 6 Daunorubicin 6 Vincristine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Etoposide 4 Busulfan 4 obinutuzumab 3 Radiotherapy 3 Neoadjuvant Therapy 3 Maintenance 3 Liquid Biopsy 3 Immunotherapy, Adoptive 3 Idarubicin 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Doxorubicin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasm, Residual × Clonal Evolution × Clear all

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡